[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,781
Citations 0
In This Issue of JAMA Neurology
September 2014


JAMA Neurol. 2014;71(9):1069. doi:10.1001/jamaneurol.2013.4166

Fu and colleagues investigate whether oral administration of fingolimod, a Food and Drug Administration–approved sphingosine 1–phosphate receptor modulator for multiple sclerosis, is safe and effective in alleviating perihematomal edema (PHE) and neurologic deficits in patients with intracerebral hemorrhage (ICH). They included 23 patients with primary supratentorial ICH with hematomal volume of 5 to 30 mL. They report that in patients with small- to moderate-sized deep primary supratentorial ICH, administration of oral fingolimod within 72 hours of disease onset was safe, reduced PHE, attenuated neurologic deficits, and promoted recovery. Editorial perspective is provided by Kevin N. Sheth, MD, and Jonathan Rosand, MD, MSc.